<div id="readability-page-1"><p>Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) insider Stuart Rich bought 2,500 shares of the business's stock in a transaction dated Thursday, December 4th. The shares were bought at an average cost of $9.20 per share, for a total transaction of $23,000.00. Following the completion of the transaction, the insider directly owned 2,500 shares of the company's stock, valued at $23,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.</p><p>Stuart Rich also recently made the following trade(s): </p><ul><li>On Wednesday, December 3rd, Stuart Rich purchased 1,500 shares of Tenax Therapeutics stock. The stock was bought at an average price of $9.08 per share, with a total value of $13,620.00. </li><li>On Tuesday, December 2nd, Stuart Rich acquired 1,000 shares of Tenax Therapeutics stock. The shares were bought at an average price of $9.01 per share, for a total transaction of $9,010.00. </li></ul><div><p><span></span><span>Get <strong>Tenax Therapeutics</strong> alerts:</span></p></div><h2>Tenax Therapeutics Trading Up 3.2%</h2><p>Shares of TENX traded up $0.30 during midday trading on Friday, hitting $9.65. The stock had a trading volume of 168,431 shares, compared to its average volume of 50,192. The business has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $6.58. The firm has a market cap of $60.25 million, a P/E ratio of -8.54 and a beta of 1.55. Tenax Therapeutics, Inc. has a fifty-two week low of $4.63 and a fifty-two week high of $9.91. </p><p>Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($1.33) by $0.93.  On average, analysts expect that  Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>TENX has been the topic of several research analyst reports. Guggenheim lowered their target price on Tenax Therapeutics from $15.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Tenax Therapeutics to a &#34;sell&#34; rating in a report on Saturday, October 25th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Tenax Therapeutics in a research note on Monday. Finally, Piper Sandler began coverage on shares of Tenax Therapeutics in a research report on Monday, September 8th. They issued an &#34;overweight&#34; rating and a $20.00 target price for the company. Three analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $18.00.</p><p><b>Get Our Latest Stock Report on TENX</b></p><h2>Institutional Investors Weigh In On Tenax Therapeutics</h2><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in  Tenax Therapeutics during the third quarter valued at about $92,000.  Citadel Advisors LLC raised its stake in  Tenax Therapeutics by 318.1% during the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company's stock valued at $329,000 after purchasing an additional 32,908 shares during the last quarter.  ADAR1 Capital Management LLC increased its holdings in shares of  Tenax Therapeutics by 98.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company's stock worth $450,000 after purchasing an additional 34,048 shares during the period.  Woodline Partners LP acquired a new stake in  Tenax Therapeutics during the third quarter worth about $671,000.  Finally, Millennium Management LLC raised its holdings in  Tenax Therapeutics by 34.2% in the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company's stock valued at $2,387,000 after acquiring an additional 79,998 shares in the last quarter. 1.67% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Tenax Therapeutics</h2> (Get Free Report)<p>Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Tenax Therapeutics</li><li>Using the MarketBeat Dividend Tax Calculator</li><li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li><li>Manufacturing Stocks Investing</li><li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li><li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li><li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tenax Therapeutics Right Now?</h2><p>Before you consider Tenax Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenax Therapeutics wasn't on the list.</p><p>While Tenax Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TENX

<p>Tenax Therapeutics insider Stuart Rich purchased 2,500 shares at $9.20 each, totaling $23,000. This transaction, disclosed to the SEC, increased his ownership significantly. Recent trades include buying 1,500 shares at $9.08 and 1,000 shares at $9.01. TENX shares rose 3.2% to $9.65. Analysts have mixed ratings, with a consensus price target of $18.00. Institutional investors have adjusted their stakes, with notable increases from Citadel Advisors and Millennium Management.</p>

Tenax Therapeutics (NASDAQ:TENX) Insider Stuart Rich Buys 2,500 Shares